Physician profile
Benjamin Parsons
NPI 1164688834
$61,741.35
in general payments reported to CMS, 2019-2025
22 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $10K · 2021: $1,426 · 2022: $509 · 2023: $620 · 2024: $525 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35,609.64 | 2019-2020 | |
| Celgene Corporation | $17,070.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $5,709.60 | 2019-2022 | |
| Seagen INC. | $1,225.00 | 2020 | |
| Genmab U.S., INC. | $715.81 | 2023-2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $316.40 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $238.18 | 2023 | Fotivda |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Pfizer INC. | $219.29 | 2021-2024 | |
| Exelixis INC. | $156.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $98.30 | 2023 | |
| Tempus Ai, INC | $72.04 | 2025 | Xt Cdx |
| Kite Pharma, INC. | $51.20 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.99 | 2022 | |
| Genentech USA, INC. | $13.86 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.